32 results about "Cell Proliferative Activity" patented technology

The invention discloses recombinant IV-type collagen as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the recombinant IV type collagen comprises a plurality of repetitive units, and the repetitive units are shown as SEQ ID NO. 1. The recombinant IV type collagen fragment is derived from human IV type collagen, heterologous amino acid residues are not introduced, and rejection and sensitization risks are avoided; meanwhile, the hydrogel also has good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, and is good in biocompatibility. In addition, the preparation method of the recombinant IV-type collagen is simple and easy to operate, and the recombinant IV-type collagen with high purity and stability can be obtained through the fermentation and purification method. Therefore, the recombinant IV type collagen disclosed by the invention has a relatively good application prospect.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention discloses a polypeptide, a recombinant XI type humanized collagen formed by the polypeptide and application of the recombinant XI type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the recombinant humanized polypeptide is designed and prepared on the basis of a natural XI type collagen core functional area, and the polypeptide can form a stable triple-helix structure. The recombinant XI type humanized collagen provided by the invention has good biological activities, including promotion of cell proliferation activity, promotion of cell adhesion activity and promotion of extracellular matrix generation or reconstruction, and is suitable for various medical or non-medical applications.

This invention relates to the field of biotechnology, specifically disclosing a novel polypeptide, recombinant XIX type humanized collagen, and their applications. This invention provides a novel polypeptide with good cell adhesion activity and the ability to promote cell proliferation. The amino acid sequence of the polypeptide comprises n repeating units; each repeating unit comprises any one of the following (1)-(3) amino acid sequences or their variants: (1) the amino acid sequence shown in SEQ ID NO.1; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO.1; (3) a variant sequence obtained by mutating one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; wherein n ≥ 1 and is an integer. The polypeptide of this invention can be used in various fields such as promoting skin barrier repair, wound healing, and epidermal renewal.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. According to the invention, through a large number of screening researches, a core functional region of a natural human XI type collagen alpha1 (XI) chain and a natural human XI type collagen alpha2 (XI) chain of a recombinant XI type humanized collagen with a triple helix structure can be formed in an in-vitro biosynthesis process. Furthermore, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The present application provides a preparation method for biosynthesis of a human body structural material. A polypeptide has the amino acid sequence of SEQ ID NO. 4, 5 or 6. Recombinant type-VII humanized collagen prepared in the present application has high activity of promoting cell proliferation and does not produce an immune response when applied to a human body, and the preparation method therefor is novel and can obtain the recombinant type-VII humanized collagen on a large scale, and is widely applied in the preparation of human body structural materials.

The present application belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant collagen XVII and a preparation method and application thereof. Specifically, a brand new recombinant collagen is designed through screening, replacement and splicing, the nucleotide sequence of the recombinant collagen is optimized according to the codon bias of Pichia pastoris, a transmembrane peptide is introduced into the amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed, and the recombinant collagen is successfully prepared through fermentation. The amino acid sequence of the recombinant collagen has a homology of 100% with the corresponding region of natural human collagen XVII, and there is no immunogenicity risk caused by sequence difference. Meanwhile, the endotoxin content of the protein can be controlled through a purification process, so that no endotoxin residue is ensured. The recombinant collagen prepared by the above technical scheme has more excellent transdermal performance and cell proliferation activity, and has better stability, and therefore has good practical application value.

The invention belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant XVII type collagen as well as a preparation method and application thereof. Specifically, brand new recombinant collagen is designed by means of screening, replacement, splicing and the like, pichia pastoris codon preference optimization is performed on a nucleotide sequence of the recombinant collagen, cell-penetrating peptide is introduced to an amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed and obtained, and the recombinant collagen is successfully prepared by fermentation. The homology of the amino acid sequence of the gene and the corresponding region of the natural human source XVII type collagen reaches 100%, and the immunogenicity risk caused by sequence difference does not exist; meanwhile, the endotoxin content of the protein can be controlled through a purification process, and no endotoxin residue is ensured. The recombinant collagen prepared by the technical scheme has more excellent transdermal performance and cell proliferation activity, and also has better stability, so that the recombinant collagen has good practical application value.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant XIII type humanized collagen and application thereof. According to the invention, a natural human XIII type collagen core functional region is obtained through a large number of screening researches. Based on the core functional area, the recombinant XIII type humanized collagen is successfully expressed and prepared for the first time. The invention relates to the field of biomedical materials, in particular to novel biomedical materials, which have good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, particularly have good proliferation promoting activity and adhesion promoting activity for skin fibroblasts and keratinocytes, and are suitable for various medical or non-medical applications, such as tissue repair / filling / compatibilization scenarios.

The invention discloses an active polypeptide OA-AL14, application and a preparation for preventing and treating skin photoaging, and belongs to the technical field of biological medicine. The active polypeptide OA-AL14 has the activity of preventing and treating skin photoaging, the amino acid sequence of the active polypeptide OA-AL14 is ALFWPMKKPWPESC, and the molecular weight of the active polypeptide OA-AL14 is 1720.06 Da; researches show that the active polypeptide has obvious ability to remove ABTS < + > free radicals and DPPH free radicals; in a UVB irradiation model test, the active polypeptide OA-AL14 shows the activity of promoting HaCaT cell proliferation and a cell protection effect, and can effectively relieve the oxidative stress reaction of the HaCaT cell induced by UVB and obviously improve the aging of the HaCaT cell induced by UVB; animal experiments further prove that the active polypeptide OA-AL14 can obviously improve UVB-induced skin photoaging, and has important value for development of novel skin photoaging prevention and treatment drugs.

The invention provides a method and system for detecting the malignant degree of endometrial cancer cells, and the method comprises the following steps: judging the influence mechanism of leptin on the malignant degree of cancer cells by detecting parameters such as leptin concentration, JAK2 / STAT3 pathway activation degree, cell proliferation activity, migration and invasion ability and the like; the dynamic association between the leptin concentration change and the activation state of the JAK2 / STAT3 signal channel can be systematically evaluated, the regulation and control effect of the channel on the proliferation, migration and invasion ability of cancer cells is effectively quantified, and a scientific basis is provided for developing treatment schemes and drugs for endometrial cancer.

Provided is a recombinant fibronectin fusion protein comprising a recombinant fibronectin mutant and platelet factor 4, wherein the recombinant fibronectin fusion protein has an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and a molecular weight of not more than 90 kDa. The recombinant fibronectin fusion protein exhibits good solubility, has a simple preparation process, and is conveniently purified. The recombinant fibronectin fusion protein comprises a new recombinant fibronectin, and can inhibit inflammation during wound healing, and promote cutaneous wound healing in mice. When platelet factor 4 is fused to the N-terminus of the recombinant fibronectin mutant, cell proliferation activity can be significantly and effectively enhanced.

The application discloses a new application of a wheat germ extract rich in polyamines, and results show that the wheat germ extract rich in polyamines can significantly increase cell migration ability, has the effects of promoting skin repair and healing, and can significantly promote skin fibroblast proliferation, has the effect of promoting cell proliferation activity; can significantly inhibit B16 cell melanin synthesis, has the effect of whitening activity; can delay skin aging, promote skin collagen production, and improve skin hyaluronic acid synthesis. It is shown that the wheat germ extract rich in polyamines prepared in the application can be prepared into health care products, food, cosmetics or medicines for skin repair, skin whitening and delaying skin aging, and a new way is provided for development and utilization of wheat germ.

The application discloses a veratramine compound, a preparation method and application thereof. The application provides a veratramine compound as shown in formula I, which can be used as a series of novel AP-1 inhibitors and used for preparing drugs for corresponding diseases. In preliminary activity research, the compound provided by the application has very strong inhibiting tumor cell proliferation activity, has the potential to be prepared into a novel antitumor drug, and has a good market prospect.

The present invention relates to an ulva australis extract with antioxidant activity and cell proliferation activity for use as a drug to prevent and / or treat neurodegenerative diseases of the retina, especially those associated with oxidative stress or loss of photoreceptors, such as age-related macular degeneration, glaucoma, inherited retinal dystrophies, diabetic retinopathy and retinitis pigmentosa.

The present patent application discloses a recombinant human collagen type I and its use. The amino acid sequence of the recombinant human collagen type I is shown in SEQ ID No: 2. The recombinant human collagen type I has good cell proliferation activity, cell migration activity, cell adhesion activity (all better than full-length recombinant human collagen type I or commercially available human collagen), and is easy to produce. The recombinant human collagen type I is expected to have the effects of whitening, moisturizing, soothing and repairing, and can be applied in the fields of cosmetics, external use drugs, skin care products, health care products, tissue engineering materials, medical devices and the like.

Provided is a method for expressing a complex of human IGF-1 and an IGF-1 binding segment of human IGFBP3 in Pichia pastoris. In order to improve the recombinant expression capacity of human IGF-1, the protein complex of IGF-1 and an IGF-1 binding segment of an endogenous binding protein IGFBP3 of IGF-1 is obtained in Pichia pastoris by means of the methods of fusion expression and co-expression of a target protein with the endogenous binding protein. The complexes obtained by means of the two expression methods in Pichia pastoris both exhibit cell proliferation activity, with the expression levels both reaching 1 g / L. The obtained protein complex of IGF-1 and the IGF-1 binding segment of IGFBP3 has thermostability, acid resistance, and alkali resistance.

The invention belongs to the technical field of biological medicine, and discloses a recombinant collagen-PDRN cross-linked hydrogel microneedle as well as a preparation method and application thereof. The microneedle comprises a needle tip layer, a needle body layer and a substrate layer, the needle tip layer is PDRN and HA, the needle body layer is recombinant III type collagen, recombinant XVII type collagen, PDRN, TG enzyme and EDC, and the substrate layer is a macromolecular HA aqueous solution. The microneedle is of a brand new designed gradient microneedle structure, the needle tip is rapidly released, the needle body is slowly degraded, the needle body adopts cross-linking compatibility of the recombinant collagen and the PDRN, and double cross-linking of TG enzyme and EDC is utilized, so that the whole microneedle has excellent mechanical performance, cell proliferation promoting activity, anti-inflammatory activity and hair growth promoting function, and has a wide prospect in anti-hair-loss and hair-growing application.

The application belongs to the technical field of genetic engineering, and particularly relates to a recombinant humanized type XVII collagen COL1115 and a preparation method thereof. The amino acid sequence of the recombinant humanized type XVII collagen COL1115 comprises the amino acid sequence shown in SEQ ID NO:1. SEQ ID NO:5 is cloned into a vector to obtain a recombinant vector; the recombinant vector is transformed into a host bacterium to obtain a recombinant engineering bacterium; and after fermentation culture and induction expression of the recombinant engineering bacterium, the recombinant humanized type XVII collagen COL1115 is obtained. The recombinant humanized type XVII collagen COL1115 prepared by the application has excellent expression performance in a Pichia pastoris expression system, can realize high-efficiency secretory expression, and is confirmed to have significant cell proliferation activity and cell adhesion activity through activity detection, thereby laying a foundation for application of the collagen in the biomedical field.

The invention relates to the technical field of biology, and particularly discloses a polypeptide, a recombinant X-type humanized collagen and application of the recombinant X-type humanized collagen. The invention provides a polypeptide which can effectively promote cell adhesion and improve cell proliferation activity. Specifically, the amino acid sequence of the polypeptide comprises n repetitive units; the amino acid sequence of the repetitive unit comprises any one of the following items (a)-(c): (a) a sequence as shown in SEQ ID NO.1 or SEQ ID NO.2; (b) a sequence obtained by adding, substituting and / or deleting one or more amino acid residues in the sequence as shown in SEQ ID NO.1 or SEQ ID NO.2 and retaining a biological activity function; and (c) a sequence which has at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the sequence as shown in SEQ ID NO.1 and retains a biological activity function. The invention provides a novel method for cartilage repair.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The invention relates to a cell membrane bionic phosphorus-containing dendrimer tumor nano vaccine as well as preparation and application thereof. The nano vaccine takes a phosphorus-containing dendrimer with peripheral blood natural killer cell proliferation promoting activity as a carrier to co-load a model antigen ovalbumin and an agonist imiquimod, and the surface of the carrier is coated with a tumor cell membrane. The molecular formula of the phosphorus-containing dendrimer is C42H42N3Na6O24P9, and the molecular weight of the phosphorus-containing dendrimer is 1389.50 g / mol. According to the invention, the raw materials are commercialized sources, the preparation method is simple, the controllability of the reaction process is high, the operation and separation are easy, and the like, and the synergistic activation of tumor drainage lymph nodes and tumor area natural killer cells, dendritic cells and tumor-related macrophages is realized by virtue of homologous targeting of cell membranes; a new thought is provided for constructing a safe and efficient anti-tumor nano vaccine with multi-dimensional cooperative regulation and control.

The invention discloses a preparation method and application of recombinant humanized VII type collagen, particularly discloses an optimized nucleotide sequence for coding M23 protein, and finds that the optimized nucleotide sequence can obviously improve the expression quantity of the M23 protein through a large amount of screening, so that the recombinant humanized VII type collagen can be used for preparing the recombinant humanized VII type collagen. And the obtained M23 has very good cell proliferation activity.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant XIII type humanized collagen and application thereof. According to the invention, a natural human XIII type collagen core functional region is obtained through a large number of screening researches. Based on the core functional area, the recombinant XIII type humanized collagen is successfully constructed and prepared for the first time. It can be used for medical or non-medical use of multiple tissue organs of the human body, for example for tissue repair / filling / compatibilization scenarios. Experimental data show that the recombinant XIII type humanized collagen provided by the invention has good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, especially has good proliferation promoting activity and adhesion promoting activity for skin fibroblasts and keratinocytes, and is suitable for various medical or non-medical applications.

The invention relates to the technical field of biology, and particularly discloses a polypeptide, a recombinant X-type humanized collagen composed of the polypeptide and application of the recombinant X-type humanized collagen. A functional unit polypeptide of the present invention comprises a humanized alpha I chain protein or a variant thereof; wherein the sequence of the humanized alpha I chain protein is SEQ ID NO: 22, and the variant comprises one or more of the following mutations relative to the humanized alpha I chain protein: sequence truncation, site mutation / substitution and sequence addition. The recombinant polypeptide taking the functional unit polypeptide as a repetitive unit can promote cell proliferation activity and cell adhesion activity, and can be used for medical or non-medical application and filling, capacity increasing or repairing scenes of a plurality of tissues and organs of a human body.

This invention relates to a humanized recombinant type I collagen, its preparation method, and its applications. The amino acid sequence of the humanized recombinant type I collagen is shown in SEQ ID NO.1 or SEQ ID NO.4, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO.5 or SEQ ID NO.6, respectively. Compared with the prior art, the humanized recombinant type I collagen of this invention can not only be stably expressed in large quantities, but also has high cell proliferation activity and excellent activity in promoting fibroblast collagen expression.

The application discloses a biological medicine use of fluvoxamine. The application obtains a series of potential IGSF11 small molecule inhibitors through artificial intelligence assisted virtual screening, wherein, the application first proposes and verifies that fluvoxamine can effectively combine IGSF11, inhibit tumor cell proliferation activity and migration and diffusion capacity, and then realizes effective tumor treatment. Experimental data also shows that fluvoxamine can expand the response rate of PD-1 monoclonal antibody to a certain extent, thereby providing a new selection and direction for clinical treatment of IGSF11 mediated tumors.